#CEITEC MU-004
SUMMARY
RNAutriX begin with screening services, generating a proprietary dataset of RNA–small molecule interactions. Develops tools for drug design, scaffold generation, and off-target prediction. In the long term, RNAutrix will develop its own RNA-targeted therapeutics and custom HTS instrumentation, contributing unique RNA–ligand insights to accelerate the future of RNA-targeted drug discovery and development.
BACKGROUND
Over 80% of disease-driving proteins remain undruggable by current small-molecule drugs, leaving critical therapeutic gaps. RNA, a master regulator of gene expression and disease biology, offers a powerful alternative. However, its structural complexity and the lack of scalable discovery tools have limited its therapeutic potential. Most RNA-targeting strategies rely on predicted secondary structures, missing the true binding potential of tertiary (3D) RNA conformations. RNAutrix addresses this challenge through a high-throughput, structure-guided platform that identifies small molecules binding to functionally folded RNA – in an unbiased, experimentally driven manner.
FEATURES AND KEY BENEFITS
- Physiologically relevant data using natural 3D structures.
- Focused on biologically meaningful targets, not random fragments.
- Fast, scalable, cost-effective, and accurate RNA-targeted drug screening.
REFERENCES
Patent pending.
AVAILABLE
Strategic Partners: Screen your libraries & co-develop RNA-targeted drugs. Investors: Support platform expansion, proprietary pipeline development, and capitalize on emerging RNA therapeutics.
CONTACT
Mohd Isar, TechTransfer@ceitec.muni.cz
Back Contact Form